000283100 001__ 283100
000283100 005__ 20251230143338.0
000283100 0247_ $$2doi$$a10.3390/diagnostics15243244
000283100 0247_ $$2pmid$$apmid:41464243
000283100 037__ $$aDZNE-2025-01507
000283100 041__ $$aEnglish
000283100 082__ $$a610
000283100 1001_ $$0P:(DE-2719)9003165$$aBendella, Zeynep$$b0$$eFirst author$$udzne
000283100 245__ $$aLongitudinal Monitoring of Brain Volume Changes After COVID-19 Infection Using Artificial Intelligence-Based MRI Volumetry.
000283100 260__ $$aBasel$$bMDPI$$c2025
000283100 3367_ $$2DRIVER$$aarticle
000283100 3367_ $$2DataCite$$aOutput Types/Journal article
000283100 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767101377_6288
000283100 3367_ $$2BibTeX$$aARTICLE
000283100 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283100 3367_ $$00$$2EndNote$$aJournal Article
000283100 520__ $$aBackground/Objectives: SARS-CoV-2 infection has been linked to long-term neurological sequelae and structural brain alterations. Previous analyses, including baseline results from the COVIMMUNE-Clin study, showed brain volume reductions in COVID-19 patients. Longitudinal data on progression are scarce. This study examined brain volume changes 12 months after baseline MRI in individuals who have recovered from mild or severe COVID-19 compared with controls. Methods: In this IRB-approved cohort study, 112 out of 172 recruited age- and sex-matched participants (38 controls, 36 mild/asymptomatic 38 severe COVID-19) underwent standardized brain MRI 12 months after baseline. Volumetric analysis was performed using AI-based software (mdbrain). Regional volumes were compared between groups with respect to absolute and normalized values. Multivariate regression controlled for demographics. Results: After 12 months, a significant decline in right hippocampal volume was observed across all groups, most pronounced in severe COVID-19 (SEV: Δ = -0.32 mL, p = 0.001). Normalized to intracranial volume, the reduction remained significant (SEV: Δ = -0.0003, p = 0.001; ASY: Δ = -0.0001, p = 0.001; CTL: minimal reduction, Δ ≈ 0, p = 0.005). Minor reductions in frontal and parietal lobes (e.g., right frontal SEV: Δ = -1.35 mL, p = 0.001), largely fell within physiological norms. These mild regional changes are consistent with expected ageing-related variability and do not suggest pathological progression. No widespread progressive atrophy was detected. Conclusions: This study demonstrates delayed, severity-dependent right hippocampal atrophy in recovered COVID-19 patients, suggesting long-term vulnerability of this memory-related region. In contrast, no progression of atrophy in other areas was observed. These findings highlight the need for extended post-COVID neurological monitoring, particularly of hippocampal integrity and its cognitive relevance.
000283100 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283100 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283100 650_7 $$2Other$$aCOVID-19
000283100 650_7 $$2Other$$aSARS-CoV-2
000283100 650_7 $$2Other$$aartificial intelligence
000283100 650_7 $$2Other$$abrain atrophy
000283100 650_7 $$2Other$$ahippocampal volume
000283100 650_7 $$2Other$$amagnetic resonance imaging
000283100 7001_ $$0P:(DE-2719)2810687$$aWidmann, Catherine Nichols$$b1
000283100 7001_ $$0P:(DE-2719)9000373$$aKindler, Christine$$b2$$udzne
000283100 7001_ $$0P:(DE-2719)9001860$$aHaase, Robert$$b3
000283100 7001_ $$0P:(DE-HGF)0$$aSauer, Malte$$b4
000283100 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael$$b5
000283100 7001_ $$0P:(DE-2719)9001861$$aRadbruch, Alexander$$b6$$udzne
000283100 7001_ $$0P:(DE-2719)9001551$$aSchmeel, Frederic Carsten$$b7$$eLast author
000283100 770__ $$aAdvancing Clinical Diagnosis with Artificial Intelligence: Applications, Challenges, and Future Directions
000283100 773__ $$0PERI:(DE-600)2662336-5$$a10.3390/diagnostics15243244$$gVol. 15, no. 24, p. 3244 -$$n24$$p3244$$tDiagnostics$$v15$$x2075-4418$$y2025
000283100 8564_ $$uhttps://pub.dzne.de/record/283100/files/DZNE-2025-1507.pdf$$yRestricted
000283100 8564_ $$uhttps://pub.dzne.de/record/283100/files/DZNE-2025-1507.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283100 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003165$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283100 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810687$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283100 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000373$$aExternal Institute$$b2$$kExtern
000283100 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001860$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283100 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000008$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283100 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001861$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283100 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001551$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283100 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283100 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIAGNOSTICS : 2022$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-29T10:48:13Z
000283100 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-29T10:48:13Z
000283100 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-29T10:48:13Z
000283100 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-29T10:48:13Z
000283100 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000283100 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000283100 9201_ $$0I:(DE-2719)5000075$$kAG Radbruch$$lClinical Neuroimaging$$x0
000283100 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x1
000283100 980__ $$ajournal
000283100 980__ $$aEDITORS
000283100 980__ $$aVDBINPRINT
000283100 980__ $$aI:(DE-2719)5000075
000283100 980__ $$aI:(DE-2719)1011303
000283100 980__ $$aUNRESTRICTED